Amixin (Tilorone) coated tablets 0.125 g. №10

Amixin (Tilorone) coated tablets 0.125 g. №10

$49.00

Manufacturer: Ukraine

Adults.

Treatment and prevention of influenza and acute respiratory viral infections, treatment of viral hepatitis A, B, C, herpes infection, cytomegalovirus infection;

as part of the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis and meningoencephalitis), urogenital and respiratory chlamydia.

To reduce the degree of immunosuppression as part of the complex therapy of diseases accompanied by secondary induced immunodeficiencies (caused by exposure to x-rays, cytostatics, surgical interventions, etc.) and require immunocorrection.

Children aged 7 to 18 years.

Treatment of influenza and acute respiratory viral infections.

Category:

Description

Ingredients

active ingredient:  tilorone, 1 tablet contains tilorone 0.125 g (125 mg).

in excipients: tablets of 125 mg: calcium hydrogen phosphate dihydrate, hypromellose (hydroxypropyl methylcellulose), microcrystalline cellulose, povidone, croscarmellose sodium, potato starch, polyethylene glycol (macrogol), talc, colloidal silicon dioxide, calcium stearate, titanium dioxide (E 171), kandurin (titanium dioxide (E 171), potassium aluminosilicate (E 555)), dye sunset yellow FCF (E 110).

Pharmacotherapeutic group

Immunostimulants. Other immunostimulants. ATX code L03A X.

Pharmacodynamics

Amixin IC (Tilorone) is an immunomodulatory and antiviral agent.

Stimulates the formation of α, β, γ-interferons in the body. The main producers of interferon in response to drug administration are intestinal epithelial cells, hepatocytes, T-lymphocytes and granulocytes. After oral administration, the maximum production of interferon is determined in the sequence “intestine – liver – blood” after 4-24 hours.

Stimulates bone marrow stem cells, depending on the dose enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-suppressors / T-helpers. Effective against a wide range of viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis A, B, C and herpes viruses. The mechanism of antiviral action is associated with inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.

In the course of animal studies (chicken and duck embryos), the high antiviral activity of the drug against the causative agent of highly pathogenic avian influenza (HPAI) of the H5N1 strain, as well as (according to experiments on chickens) a significant immunostimulatory and adjuvant activity against HPAI pathogen antigens, has been proven.

Pharmacokinetics

After oral administration, tilorone is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug binds to plasma proteins.

The drug does not undergo biotransformation and does not accumulate in the body. It is excreted almost unchanged with faeces and urine in a ratio of 7:1. The half-life is 48 hours.

Indications

Adults.

Treatment and prevention of influenza and acute respiratory viral infections, treatment of viral hepatitis A, B, C, herpes infection, cytomegalovirus infection;

as part of the complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis and meningoencephalitis), urogenital and respiratory chlamydia.

To reduce the degree of immunosuppression as part of the complex therapy of diseases accompanied by secondary induced immunodeficiencies (caused by exposure to x-rays, cytostatics, surgical interventions, etc.) and require immunocorrection.

Children aged 7 to 18 years.

Treatment of influenza and acute respiratory viral infections.

Contraindications

Hypersensitivity to the active substance or to any of the components of the drug. During pregnancy and breastfeeding. Age up to 7 years.

Directions

Amixin IC (Tilorone) is taken orally after a meal.

In adults

In the treatment of influenza and acute respiratory viral infections  in the first 2 days of treatment – 125 mg, then – 125 mg after 48 hours. Heading dose – 750 mg.

For the prevention of influenza and acute respiratory viral infections:  125 mg once a week for 6 weeks.

Treatment of viral hepatitis A:  on the 1st day of treatment – 125 mg 2 times, then – 125 mg every 48 hours. Heading dose – 1.25 g.

Prevention of viral hepatitis A:  125 mg once a week for 6 weeks.

Treatment of acute hepatitis B: in the first 2 days of treatment – 125 mg, then – 125 mg after 48 hours. Heading dose – 2 g. With a protracted course of the disease, the course dose can be increased to 2.5 g.

In chronic hepatitis B:  in the first 2 days of treatment – 250 mg, then – 125 mg every 48 hours. The course dose at the beginning of treatment is 2.5 g. Further, the drug is prescribed at a dose of 125 mg per week. In general, the course dose is 3.75 g to 5 g.

In acute hepatitis C:  in the first 2 days of treatment – 125 mg, then – 125 mg every 48 hours. Therapeutic dose – 2.5 g.

In chronic hepatitis C: in the first 2 days of treatment – 250 mg, then – 125 mg after 48 hours. The course dose at the beginning of treatment is 2.5 g. Further, the drug is prescribed at a dose of 125 mg per week. In general, the course dose is 5 g.

For the treatment of herpetic, cytomegalovirus infection:  in the first 2 days of treatment – 125 mg, then – 125 mg after 48 hours. Heading dose – 2.5 g.

In the complex therapy of neuroviral infections – infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis and meningoencephalitis): in the first 2 days of treatment – 125 mg, then – 125 mg after 48 hours. Heading dose – from 1.5 to 1.75 g.

In the complex therapy of urogenital and respiratory chlamydia: in the first 2 days of treatment – 125 mg, then – 125 mg after 48 hours. Heading dose – 1.25 g.

To reduce the degree of immunosuppression as part of the complex therapy of diseases accompanied by secondary induced immunodeficiencies and require immunocorrection:  125-250 mg per week for 6 weeks. The maximum course dose is 1.5 g. Depending on the immunological parameters and the course of the disease, the course of treatment can be repeated with an interval between courses of 4 weeks.

Children aged 7 to 18 years.

In uncomplicated forms of influenza or SARS: 60 mg 1 time per day on the 1st, 2nd, 4th day from the start of treatment. Heading dose – 180 mg.

In the event of complications of influenza or SARS: 60 mg 1 time per day on the 1st, 2nd, 4th and 6th day from the start of treatment. Heading dose – 240 mg.

Related products